Treatments
926 articles
PARP Inhibitors for Pancreatic Cancer Maintenance Treatment
Dr. Kim Reiss Binder is leading a clinical trial of maintenance treatment with the PARP inhibitor rucaparib, for patients who carry the BRCA mutation.
Multicenter Trial Focuses on Neoadjuvant Treatment for Borderline Resectable and Locally Advanced Disease
Dr. David Ryan outlines a new trial for pre-surgical pancreatic cancer treatment combining a blood pressure drug, immunotherapy, standard care and SBRT.
A Simple Blood Test for Early Detection of Eight Cancers Shows Promise
Dr. Anne Marie Lennon explains the CancerSEEK blood test, a liquid biopsy in clinical trials for early detection of eight cancers, including pancreatic.
An Immunotherapy Game Changer
Immunotherapy with Keytruda (pembrolizumab) is approved for use in cancer patients with certain genetic defects in their tumors.
Understanding a Family’s Risk for Pancreatic Cancer
A tumor registry studies the genetics of pancreatic cancer to determine risk factors for families.
Why You Need This Simple Blood Test at Diagnosis
An important factor in determining which treatment to use for pancreatic cancer patients is measuring the level of tumor marker CA-19-9. Learn more here.
A Clinical Trial Gives Me Hope
When Dennis Rues’s pancreatic cancer recurred, his doctors recommended that he join a clinical trial. Now he’s doing well.
Choosing the Right Doctor
Rita Krueger made an important decision that changed her pancreatic cancer treatment when she got a second opinion.
A Clinical Trial Saved My Life
Bob Minetti and his doctors believe that a clinical trial saved his life after a pancreatic cancer diagnosis.
The Importance of a Good Treatment Team
Wayne Mullis credits his treatment team with choosing the best pancreatic cancer treatment for him and for helping him through treatment.
Let’s Win! Pancreatic Cancer Survivors Series—Year Two
Meet more long-term survivors of pancreatic cancer, as well as the doctors and researchers who are working tirelessly to create new and better treatment options.
Targeted Therapy to Inhibit Connective Tissue Growth in Pancreatic Cancer
Researchers are testing a new antibody, a type of targeted therapy, in combination with standard treatment for pancreatic cancer in a phase III trial.
A Maintenance Trial for Patients with BRCA or PALB2 Mutations
A clinical trial examines whether the PARP inhibitor rucaparib can work as a maintenance drug for pancreatic cancer patients with BRCA or PALB2 mutations.
Testing a Signal-Inhibiting Drug on Tumors with Specific Mutations
A new drug for certain tumor mutations is being tested in a type of clinical trial called a basket trial, which matches tumor genetics and drugs.
Kerri Kaplan
Kerri Kaplan is the President of the Lustgarten Foundation, which is America’s largest private funder of pancreatic cancer research and is relentlessly focused on improving patient outcomes. Kerri oversees all aspects of the Lustgarten Foundation’s operational activities, including major fundraising initiatives, patient outreach, and the Foundation’s in-depth research portfolio. Early in her career at the […]